Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma
Allison Fa. O’Neill·John D. Gordan·Kimberly J. Riehle·Alanna J. Church·Heung Bae Kim·Anne E. Gill·Arun Rangaswami·James I. Geller·Mark Yarchoan·Michael V. Ortiz·Emily L. Zeme·G K Abou-Alfa·William P. Harris·Alexander J. Bondoc·Cristina R. Ferrone·Michael S. Torbenson·Sunyoung S. Lee·Abby R. Rosenberg·Marina Baretti·Megan Fitzgerald·Kevin Liu
INTRODUCTION Fibrolamellar carcinoma (FLC) is a rare primary liver cancer with distinctive histology, molecular biology, and clinical presentation that predominantly affects adolescents and young adults. Its characteristic histology was first described by Edmondson in 1956 following resection of a liver carcinoma from a 14-year-old patient.1 It was subsequently described as a distinct clinical and histological subtype of conventional hepatocellular carcinoma (HCC) in 1980 by Craig et al.2 based